Literature DB >> 11588051

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.

P Ruf1, H Lindhofer.   

Abstract

Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. This study demonstrates that the trifunctional bsAb BiLu is able to kill tumor cells very efficiently without any additional costimulation of effector cells in vitro and in vivo. Remarkably, this bsAb also induces a long-lasting protective immunity against the targeted syngeneic mouse tumors (B16 melanoma and A20 B-cell lymphoma, respectively). A strong correlation was observed between the induction of a humoral immune response with tumor-reactive antibodies and the survival of mice. This humoral response was at least in part tumor specific as shown in the A20 model by the detection of induced anti-idiotype antibodies. Both the survival of mice and antitumor titers were significantly diminished when F(ab')(2) fragments of the same bsAb were applied, demonstrating the importance of the Fc region in this process. With the use of T-cell depletion, a contribution of a cellular antitumor response could be demonstrated. These results reveal the necessity of the Fc region of the bsAb with its potent immunoglobulin subclass combination mouse immunoglobulin G2a (IgG2a) and rat IgG2b. The antigen-presenting system seems to be crucial for achieving an efficient tumor cell killing and induction of long-lasting antitumor immunity. Hereby, the recruitment and activation of accessory cells by the intact bsAb is essential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588051     DOI: 10.1182/blood.v98.8.2526

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Authors:  Klaus Pietzner; Ignace Vergote; Armando Santoro; Radoslav Chekerov; Frederik Marmé; Per Rosenberg; Holger Martinius; Hilke Friccius-Quecke; Jalid Sehouli
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

Review 2.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

Review 4.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 5.  Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.

Authors:  Gert Riethmüller
Journal:  Cancer Immun       Date:  2012-05-01

Review 6.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

7.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 8.  Antibody-based immunotherapy of cancer.

Authors:  Louis M Weiner; Joseph C Murray; Casey W Shuptrine
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

9.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

10.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Authors:  Peter Ruf; Michael Kluge; Michael Jäger; Alexander Burges; Constantin Volovat; Markus Maria Heiss; Jürgen Hess; Pauline Wimberger; Birgit Brandt; Horst Lindhofer
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.